Halomethasone (C 48.401-Ba) for the topical treatment of common dermatoses.

Abstract

C 48.401-Ba cream, containing 0.05% halomethasone was compared in a double-blind between-patients trial with a cream containing 0.1% betamethasone valerate in forty-eight patients suffering from atopic dermatitis and in thirty-nine patients suffering from seborrhoeic dermatitis. A similar comparison was made with ointments containing the same concentration of active ingredient in forty-six patients suffering from atopic dermatitis. Both ointments were also compared in a within-patient double-blind trial in thirty patients suffering from psoriasis. The analysis of the results showed that for the treatment of the above-mentioned dermatoses, both drugs, the cream as well as the ointment, are equally effective and well tolerated.

• Authors: M de la Brassine, A Kint, J M Lachapelle, D Tennstedt
• Journal: The Journal of international medical research (J Int Med Res) Vol. 12 Issue 5 Pg. 307-9 ( 1984) ISSN: 0300-0605 [Print] England
• PMID: 6238861 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Betamethasone
• Betamethasone Valerate
• halometasone

Topics

• Administration, Topical
• Anti-Inflammatory Agents (therapeutic use)
• Betamethasone (analogs & derivatives, therapeutic use)
• Betamethasone Valerate (therapeutic use)
• Clinical Trials as Topic
• Dermatitis, Atopic (drug therapy)
• Dermatitis, Seborrheic (drug therapy)
• Double-Blind Method
• Humans
• Psoriasis (drug therapy)